5 Best Pharmaceutical Stocks to Buy According to Cathie Wood

Page 1 of 5

In this article we discuss the 5 best pharmaceutical stocks to buy according to Cathie Wood. If you want to read our detailed analysis of Wood’s history and hedge fund performance, go directly to the 10 Best Pharmaceutical Stocks to Buy According to Cathie Wood.

At Insider Monkey we leave no stone unturned when looking for the next great investment idea. For example, advertising technology one of the fastest growing industries right now, so we are checking out stock pitches like this under-the-radar adtech stock that can deliver 10x gains. We go through lists like the 10 best hydrogen fuel cell stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage. Keeping this in mind, let’s take a look at Cathie Wood’s top pharma stock picks:

5. CRISPR Therapeutics AG (NASDAQ: CRSP)

Wood’s Stake Value: $1,010,179,000
Percentage of Cathie Wood’s 13F Portfolio: 2.0065%
Number of Hedge Fund Holders: 27

CRISPR Therapeutics AG (NASDAQ: CRSP) develops gene-based medicines and was founded in 2013. It is ranked fifth on our list of 10 best pharmaceutical stocks to buy, according to Cathie Wood. CRISPR stock has returned more than 73% to investors during the course of the past twelve months.

In May, Evercore ISI upgraded the stock to “Outperform” as it believes that CRISPR would be the first to get approval for gene editing product. Further, CRISPR and Nkarta, Inc. (NASDAQ: NKTX) will develop CRISPR/Cas9 gene-edited cell therapies to cure cancer. In April, Jefferies upgraded the stock to “Buy” from “Hold.” 

The hedge fund run by Wood owns more than 8.2 million shares in the media company worth over $1 billion, representing 2% of their investment portfolio. ARK Investment has reduced its activity on CRISPR stock by 21% in the past quarter.

Page 1 of 5